Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics' stock has experienced several key events in the past six months. The stock price increased by 65.87% between December 24, 2024, and December 23, 2025. The U.S. FDA permitted RAP-219 to advance into Phase 3 registrational trials for focal onset seizures, expected to commence in Q2 2026, and the company is expanding its epilepsy portfolio to include primary generalized tonic-clonic seizures (PGTCS). Positive Phase 2a focal onset seizure data for RAP-219 contributed to modest stock gains. Strong clinical trial results for RAP-219 in Phase II FOS data were reported, demonstrating significant reductions in seizure-like events and a 24% seizure freedom rate in a refractory patient population. Analyst ratings for RAPP have been predominantly positive, with a consensus of "Moderate Buy" or "Strong Buy" and an average target price of $48.33. Insider trading activity shows more sales than purchases, with CEO Abraham Ceesay and CSO David Bredt selling shares, while founder Steven M. Paul and Reid M. Huber made purchases.

Rapport Therapeutics, Inc. does not currently have products or services on the market subject to demand seasonality, as its business model is centered on the ongoing clinical development and potential discovery of new drug candidates.

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines for central nervous system (CNS) disorders. The company operates in the Health Care sector, specifically in the Biotechnology and Pharmaceutical Preparations industry, leveraging neuronal receptor biology and receptor-associated proteins (RAPs) to target specific neuroanatomical regions. Rapport's lead investigational drug, RAP-219, is in clinical development for focal onset seizures in patients with epilepsy, bipolar mania, and diabetic peripheral neuropathic pain. The company is also developing RP4010 for major depressive disorder (MDD) and generalized anxiety disorder (GAD), along with discovery-stage programs targeting chronic pain and hearing disorders.

Rapport Therapeutics, Inc. is headquartered in Boston, Massachusetts, with additional operations in San Diego, California, and maintains a strategic partnership network.

Rapport Therapeutics has maintained a generally positive brand reputation over the past year, driven by its scientific advancements and clinical trial progress. The company has received a consensus rating of "Moderate Buy" or "Strong Buy" from analysts, indicating positive sentiment within the financial community, and positive news sentiment is noted with increased news coverage. Key events that have positively affected Rapport Therapeutics' reputation include the FDA's permission to advance RAP-219 into Phase 3 registrational trials, positive Phase 2a clinical trial results for RAP-219, expansion of its epilepsy portfolio, and regular participation in high-profile industry conferences. Insider selling has not significantly impacted the overall positive analyst sentiment or the company's perceived potential.

Rapport Therapeutics (NASDAQ: RAPP) is primarily owned by institutional shareholders (103.39%) and Rapport Therapeutics insiders (33.86%), with no retail investor ownership reported. As of December 2025, 237 institutional owners and shareholders held a total of 51,508,909 shares. Major institutional owners include Third Rock Ventures V LP, TRV GP V LLC, Fmr LLC, Arch Venture Partners XII LLC, Arch Venture Management LLC, Capital International Investors, Cormorant Asset Management LP, Goldman Sachs Group Inc, Sofinnova Investments Inc, Johnson & Johnson, Vanguard Group Inc, and BlackRock, Inc. Key individual insiders with significant holdings include Third Rock Ventures V LP and James Healy.